Q3 beat; promising growth across the key offerings
30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."
Pages
64
Language
English
Published on
30/10/24
You may also be interested by these reports :
06/02/26
Coloplast delivered a weak Q1, with both revenue and adjusted EBIT missing consensus. Organic growth of 6% was in line with expectations, but ...
06/02/26
Qiagen’s Q4 results surpassed both market expectations and management’s guidance, with most segments reporting gains. The 2026 guidance aligns with ...
05/02/26
GN’s Q4 results fell short of market expectations. While Hearing experienced healthy growth, this was overshadowed by weaknesses in Gaming and ...
05/02/26
Our estimates have been moderated following the Q4 25 miss, primarily reflecting a softer order book and growth momentum (especially for the LS ...